To investigate the pharmacokinetic characteristics of a single oral dose of beraprost sodium tablets (test preparation, strength: 40 μg) produced by Hunan Warner Pharmaceutical Co., Ltd. and a single oral dose of beraprost sodium tablets (reference preparation, strength: 40 μg) certified by Takeda Tebafa Co., Ltd. in healthy subjects under fasting and postprandial conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.

Start Date25 Apr 2024

Sponsor / Collaborator

Hunan Warrant Pharmaceutical Co., Ltd.

CTR20240237

/ CompletedNot Applicable

健康受试者空腹和餐后状态下单剂量口服贝前列素钠片（40μg）的随机、开放、两制剂、两序列、四周期、完全重复交叉生物等效性试验

[Translation] A randomized, open-label, two-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of a single oral dose of beraprost sodium tablets (40 μg) in healthy subjects in the fasting and fed state

主要目的：比较空腹和餐后单次给药条件下，北京康晟百春生物科技有限公司持证的贝前列素钠片（规格：40μg，受试制剂）与武田テバファーマ株式会社(Teva Pharma Japan Inc)持证的贝前列素钠片（规格：40μg，参比制剂）在健康受试者中吸收程度和速度的差异。通过主要药代动力学参数，评价两者是否生物等效。次要目的：通过观察健康受试者单次口服受试制剂和参比制剂后的安全性指标，评价贝前列素钠片的安全性。

[Translation]

Primary objective: To compare the differences in absorption extent and rate of beraprost sodium tablets (specification: 40μg, test preparation) certified by Beijing Kangsheng Baichun Biotechnology Co., Ltd. and beraprost sodium tablets (specification: 40μg, reference preparation) certified by Takeda Teva Pharma Japan Inc. (Teva Pharma Japan Inc) in healthy subjects under the conditions of single administration on an empty stomach and after a meal. To evaluate whether the two are bioequivalent by the main pharmacokinetic parameters. Secondary objective: To evaluate the safety of beraprost sodium tablets by observing the safety indicators of healthy subjects after a single oral administration of the test preparation and the reference preparation.

Start Date23 Feb 2024

Sponsor / Collaborator

Beijing Kangsheng Baichun Biotechnology Co., Ltd.

CTR20234207

/ CompletedNot Applicable

贝前列素钠片在中国健康受试者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列交叉的人体生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose (fasting/postprandial) oral bioequivalence study of beraprost sodium tablets in healthy Chinese subjects, with two formulations and two sequences crossed over

1. 主要目的：观察中国健康受试者在空腹/餐后状态下单次口服受试制剂贝前列素钠片（规格：20μg）和参比制剂贝前列素钠片（商品名：德纳®，规格：20μg，持证商：Toray Industries, Inc.）后的药代动力学特征，评价空腹/餐后状态下两种制剂的生物等效性。 2. 次要目的：观察受试制剂贝前列素钠片和参比制剂贝前列素钠片（德纳®）在中国健康受试者中的安全性。

[Translation]

1. Primary objective: To observe the pharmacokinetic characteristics of the test preparation Beraprost Sodium Tablets (specification: 20μg) and the reference preparation Beraprost Sodium Tablets (trade name: Dena®, specification: 20μg, licensee: Toray Industries, Inc.) after a single oral administration in Chinese healthy subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. 2. Secondary objective: To observe the safety of the test preparation Beraprost Sodium Tablets and the reference preparation Beraprost Sodium Tablets (Dena®) in Chinese healthy subjects.

Start Date27 Dec 2023

Sponsor / Collaborator

Shandong Bestcomm Pharmaceutical Co., Ltd.

100 Clinical Results associated with Beraprost Sodium

100 Translational Medicine associated with Beraprost Sodium

100 Patents (Medical) associated with Beraprost Sodium

1,094

Literatures (Medical) associated with Beraprost Sodium

01 Nov 2024·Microcirculation

Effects of Beraprost on Intestinal Microcirculation and Barrier Function in a Mouse Model of Renal Failure

Article

Author: Nagasu, Hajime ; Yamamoto, Toshiya ; Takasu, Masanobu ; Hirano, Akira ; Sasaki, Tamaki ; Matsuura, Takumi ; Kadoya, Hiroyuki ; Tatsugawa, Rie ; Iwakura, Tsukasa ; Kajimoto, Eriko ; Kashihara, Naoki ; Kishi, Seiji ; Kurumatani, Hajimu ; Kidokoro, Kengo

ABSTRACTObjectiveEndothelial dysfunction plays an important role in the pathogenesis of chronic kidney disease. Prostacyclin (PGI2), an endothelial cell‐produced endogenous prostaglandin, plays a crucial role in maintaining endothelial function. However, its effects on intestinal microcirculation and barrier function are not fully understood. We hypothesized that PGI2 improves intestinal microcirculation and barrier function via endothelial protective effects.MethodsICR and ICGN (a spontaneous nephrotic model) mice were used in this study. Intestinal microcirculation was visualized in vivo to investigate PGI2 effects. Beraprost served as PGI2. PGI2 administration spanned 4 weeks, following which we assessed its influence on intestinal endothelial, intestinal barrier, and renal functions.ResultsWe visualized intestinal microcirculation and endothelial glycocalyx in the intestinal blood vessels. Beraprost administration induced a 1.2‐fold dilatation of the vascular diameter of the small intestine. Intestinal blood flow in ICGN mice was significantly reduced compared that in ICR mice but improved with beraprost administration. ICGN mice exhibited reduced serum albumin levels, decreased ambulation, an imbalance in intestinal reactive oxygen species (ROS)/nitric oxide (NO), and impaired tight junctions; all were ameliorated by beraprost administration.ConclusionsBeraprost improves intestinal microcirculation and barrier function by ameliorating ROS/NO imbalances, thereby reducing physical inactivity during renal failure.

31 Oct 2024·Drug Discoveries & Therapeutics

General selection criteria for safety and patient benefit [XⅢ]: Comparing the formulation characteristics of brand-name and generic bifonazole creams

Article

Author: Nozawa, Marika ; Ishii, Fumiyoshi ; Shimokawa, Ken-ichi ; Ichimura, Natsuki ; Nozawa, Mitsuru ; Imanaka, Yuko Wada

A comparative evaluation of the brand-name drug Mycospor and six generic drugs (IWAKI, Bifonol, F, YD, Sawai, and TEVA), all comprising a cream formulation containing the antifungal drug bifonazole, was performed based on physicochemical measurements. The pH of the various formulations was significantly higher for the generics Bifonol (pH 7.1), Sawai (pH 6.7), and TEVA (pH 7.3) and significantly lower for YD (pH 4.3) than for the brand-name drug Mycospor (pH 5.5). The viscosity of the various formulations was significantly higher for TEVA (25,011 mPa·s) versus Mycospor (22,376 mPa·s) and significantly lower for IWAKI, Bifonol, F, YD, and Sawai, with Bifonol (8,572 mPa·s) being particularly low. Considering the hysteresis loop area obtained for the shear rate vs. shear stress, which represents the thixotropic properties, and using the value of Mycospor as the reference for 100%, YD (179%), Sawai (557%), and TEVA (201%) showed significantly higher values. Furthermore, the membrane permeability of bifonazole at 24 hours was significantly higher for Bifonol (309 μg/mL) and F (182 μg/mL) and significantly lower for Sawai (124 μg/mL) and TEVA (92 μg/mL) than for Mycospor (153 μg/mL). Finally, optical micrographs showed that the dispersion of particles was similar in the various formulations, but the particles of F and TEVA were uniformly dispersed with a smaller particle size than the other formulations. Overall, significant differences were observed in the formulation characteristics between the brand-name drug and generic drugs, which were attributed to differences in the manufacturing process and the types of additives.

01 Jul 2024·Journal of Veterinary Internal Medicine

Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment

Article

Author: Teshima, Takahiro ; Saito, Takahiro ; Suzuki, Ryohei ; Yuchi, Yunosuke ; Satomi, Shuji ; Horikawa, Rina ; Matsumoto, Hirotaka

AbstractAn 8‐year‐old Leonberger receiving immunosuppressive treatment with clinical signs of acute dyspnea, cyanosis, and difficulty standing was referred to our institution (Day 1). Treatment including oxygen, clopidogrel, and low‐molecular‐weight heparin was initiated for suspected pulmonary thrombosis. However, exertional dyspnea persisted until Day 10, and increased tricuspid regurgitation velocity, pulmonary vascular resistance, and McConnell's signs also were observed. Thus, beraprost sodium was administered PO on Day 11 to treat suspected pulmonary hypertension. On Day 13, contrast‐enhanced computed tomography identified extensive contrast defects in the pulmonary arteries, and IV monteplase was administered on Days 14 and 18, with marked improvement in respiratory status and exertional dyspnea on Day 20. Right ventricular function and McConnell signs also improved, and tricuspid regurgitation velocity and pulmonary vascular resistance decreased. On Day 250, echocardiography indicated further improvement in pulmonary hypertension pathophysiology. The patient was still progressing well with antithrombotic and pulmonary vasodilator treatment 400 days later.

News (Medical) associated with Beraprost Sodium

17 Mar 2025

·www.fiercepharma.com

The top 10 drugs losing US exclusivity in 2025

The end of the U.S. patent runway is nearing for 10 industry blockbusters in 2025. While each year features high-profile losses of exclusivity in the pharma industry, this year's list is something of a doozy.For one, Johnson & Johnson's Stelara is already facing off against several biosimilars, and several more are yet to come as the year plays out. With $6.72 billion in U.S. sales in 2024, the drug is the largest U.S. loss of exclusivity since AbbVie's megablockbuster Humira tumbled over the patent cliff in early 2023. Johnson & Johnson had previously warned of a "late 2023" patent cliff for Stelara, but the company was able to squeeze more life out of its key immunology moneymaker through a series of legal settlements.Johnson & Johnson's not alone in losing U.S. market exclusivity on a key sales driver this year. Also facing ongoing or future declines for their top revenue generators are Regeneron with eye drug Eylea, Amgen with bone medicines Prolia/Xgeva and Novartis with heart failure therapy Entresto. Eylea already faces its first U.S. biosimilar after Amgen launched Pavblu in November. Fierce Pharma chose to include Eylea in this report—despite the biosimilar launch happening last year—because the commercial situation is still playing out for Regeneron and to not exclude a key development in an important market.Amgen, for its part, collected $4.39 billion in revenue from its key bone medicines Prolia and Xgeva last year. While the company has built its own impressive biosimilar business over the years, it'll have to play an unfamiliar role and watch copycat drugs eat away at the market for its originators starting in late May and early June.Novartis, meanwhile, has warned of a "mid-2025" loss of U.S. exclusivity for Entresto as a key combination patent nears its expiration this summer. Besides Entresto, Novartis has two other big-selling products on this list in Promacta and Tasigna.Moving down the list, readers will likely notice two high-profile drugs from AstraZeneca. Rare disease medicine Soliris, picked up in AZ's buyout of Alexion, is set to face its first biosimilar from Amgen sometime in the second quarter. And Brilinta, a cardiometabolic drug once pegged to be a key blockbuster but that never quite met expectations, is also running out of its U.S. patent protections in the near future.For one measure of the high-profile nature of the drugs on this list, look no further than last year's version of the report. With $1.45 billion in prior-year U.S. sales, Bristol Myers Squibb's Sprycel led the 2024 group. But, if compared against the 2025 class of patent expirations, Sprycel would rank No. 6. There are always uncertainties in compiling this report due to the unpredictable nature of patent litigation and regulatory interactions. This year, the drug with the most apparent uncertainty is J&J's Simponi and Simponi ARIA. That medicine's inclusion hinges on a potential fourth-quarter approval—and launch—of Teva and Alvotech's AVT05. We opted to include the medicine because a key patent has already expired, and a reputable biosimilar team is marching through the regulatory process.To compile this report, Fierce Pharma parsed company filings, presentations and conference call transcripts. We also used published research from pharmacy benefit manager OptumRx and healthcare services firm Cardinal Health. The report ranks the top U.S. losses of exclusivity based on U.S. sales from the prior year.

Patent ExpirationPatent InfringementAcquisition

25 Feb 2025

·endpts.com

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. The lawsuit , filed Monday in federal district court, claims that Samsung violated a settlement agreement between the two parties by trying to sublicense the rights to a Stelara biosimilar to a private label provider. The 2023 agreement had allowed Samsung to launch its biosimilar product Pyzchiva in February this year, but barred it from sublicensing biosimilars to third parties. The action comes amid a flurry of Stelara biosimilar launches starting in January that are set to erode sales of the medicine, which has been a top-seller for J&J since 2019. Amgen’s Stelara biosimilar Wezlana was the first to launch last month. Nuvaila — Optum Rx’s biosimilar business — is selling Wezlana under a private label . The biosimilar versions come with a wide variety of list prices , from 5% off the branded price to between 86% and 90% off. J&J secured FDA approval for Stelara for the treatment of psoriasis in 2009. It later won label expansions for psoriatic arthritis, ulcerative colitis and Crohn’s disease. The IL-12/IL-23 targeting monoclonal antibody reached $10.9 billion in sales at its peak in 2023. But key patents started expiring that same year, opening the door for cheaper versions. Samsung’s partner Sandoz announced the US launch of Pyzchiva on Monday. In a statement shared with the media on Tuesday, J&J said it is seeking an injunction against Samsung for trying to sublicense “a second, additional product” to a pharmacy benefit manager’s private label distributor. The drugmaker stressed it is not trying to stop Samsung from selling Pyzchiva. Samsung declined to comment on the ongoing litigation. Teva and Alvotech’s biosimilar Selarsdi was launched last week. On Monday, Biocon Biologics launched its biosimilar Yesintek. The FDA has approved a total of seven Stelara biosimilars so far. Editor’s Note: This article was updated to add more context on Amgen’s Wezlana.

Drug ApprovalPatent InfringementPatent ExpirationBiosimilarLicense out/in

22 Feb 2025

·pipelinereview.com

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

REYKJAVIK, Iceland and PARSIPPANY, NJ, USA I February 21, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI ™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara ® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara ® , following the expiration of exclusivity for the first interchangeable biosimilar, on April 30, 2025. “Biosimilars like SELARSDI create opportunities for cost savings across the healthcare system, and we are proud to be able to introduce our second biosimilar treatment option in partnership with Alvotech to U.S. patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. “The U.S. availability of SELARSDI reinforces Teva’s overall strategy to identify strategic business partners to develop and manufacture biosimilars while leveraging Teva’s commercial presence and experience to bring this and other products to the U.S. market.” “The U.S. launch of SELARSDI is an important step for our partnership and reaffirms a joint commitment to providing more affordable treatment options for U.S. patients,” said Anil Okay, Chief Commercial Officer for Alvotech. “Alvotech’s fully integrated approach to development and manufacturing, coupled with our focus on biosimilars, enables us to continue expanding a portfolio of high-quality biologics and contribute meaningfully to lowering healthcare costs world-wide.” SELARSDI is approved by the U.S. Food and Drug Administration (FDA) in several presentations, matching the approved presentations of the reference biologic Stelara (ustekinumab). The FDA has provisionally determined that all presentations of SELARSDI can be approved as interchangeable to Stelara ® (ustekinumab) injection upon expiry of exclusivity on April 30, 2025, for the first interchangeable biosimilar. The four approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and 130 mg/26 mL in a single-dose vial for intravenous infusion. Ustekinumab is a human monoclonal antibody (mAb) that selectively targets the p40 protein, a component common to both interleukin (IL)-12 and IL-23 cytokines, which play crucial roles in treating immune-mediated diseases like psoriasis and psoriatic arthritis, and inflammatory diseases like Crohn’s disease and ulcerative colitis. Alvotech developed and produces SELARSDI using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara ® . 1 In August 2020, Teva and Alvotech entered into a strategic partnership for the exclusive commercialization of five Alvotech biosimilar product candidates, and in July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products. Alvotech manages development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., leveraging the experience and extensive sales and marketing infrastructure from Teva. Two biosimilars developed under the partnership have been given U.S. FDA approval: most recently, SELARSDI in April 2024; and in February 2024, SIMLANDI ® (adalimumab-ryvk), the first high-concentration, citrate-free interchangeable biosimilar to Humira ® , which was launched in the U.S. in May 2024. About SELARSDI™ (ustekinumab-aekn) SELARSDI is a monoclonal antibody and a biosimilar to Stelara ® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses. 2 The biosimilar has been launched in Canada as JAMTEKI™, in Europe as UZPRUVO ® and in Japan as USTEKINUMAB BS (F). It has been approved in the U.S. as SELARSDI. Applications are also under review in multiple countries globally. Use of Trademarks Stelara ® is a registered trademark of Johnson & Johnson. Humira ® is a registered trademark of AbbVie Biotechnology Ltd. JAMTEKI™ is a trademark of JAMP Pharma Group. UZPRUVO ® is a registered trademark of STADA and Alvotech. SELARSDI INDICATIONS AND SAFETY INFORMATION INDICATIONS SELARSDI™ (ustekinumab-aekn) Injection, is a human interleukin-12 and -23 antagonist indicated for: • the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. • the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. • the treatment of adult patients with moderately to severely active Crohn’s disease. • the treatment of adult patients with moderately to severely active ulcerative colitis. Please click here for full Prescribing Information for SELARSDI. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we’re already working to address it. To learn more about how Teva is all in for better health, visit www.tevapharm.com . About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars to Humira ® (adalimumab) and Stelara ® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com . None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube . Sources SOURCE: Teva Pharmaceutical Industries

Drug ApprovalBiosimilarLicense out/inPatent ExpirationNDA

100 Deals associated with Beraprost Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D01551	Beraprost Sodium	B01AC19	DB05229

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peripheral Vascular Diseases	China	Toray Industries, Inc.	15 Aug 2003
Pulmonary Arterial Hypertension	China	Toray Industries, Inc.	15 Aug 2003
Hypertension, Pulmonary	Japan	Kaken Pharmaceutical Co., Ltd.	22 Sep 1999
Occlusion of artery	Japan	Kaken Pharmaceutical Co., Ltd.	21 Jan 1992

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerular disease	Discovery	Hong Kong	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	Taiwan Province	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	Japan	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	Malaysia	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	Thailand	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	China	Toray Industries, Inc.	01 Mar 2010
Glomerular disease	Discovery	South Korea	Toray Industries, Inc.	01 Mar 2010
Nephrosclerosis	Discovery	Hong Kong	Toray Industries, Inc.	01 Mar 2010
Nephrosclerosis	Discovery	Taiwan Province	Toray Industries, Inc.	01 Mar 2010
Nephrosclerosis	Discovery	South Korea	Toray Industries, Inc.	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00989963 (CTgov)	Phase 2	Pulmonary Arterial Hypertension	36	Beraprost Sodium Modified Release	vunpedzxmt(orjqfxjrbo) = reoamszntd natystgcks (zsturyldds, osbwsfpdvn - xvaqoimlzq) View more	-	30 Sep 2020
NCT00792571 (CTgov)	Phase 2	Pulmonary Arterial Hypertension	18	Beraprost Sodium	mmhcisuqed(khjafcumdj) = wijawqdqyr ibzhpfymdh (atipvtpzjg, ubzabtnyku - jvnjmzqkbr) View more	-	26 Dec 2019
MP556 (ERA2017)	Not Applicable	-	-	Beraprost sodium 40ug	tjockgqtxn(kaosunnifn) = tvtymvmpaj wqfpkbhtmt (ddklenkppd )	Positive	26 May 2017
				BERAPROST SODIUM (Control group)	tjockgqtxn(kaosunnifn) = wnhmawgcno wqfpkbhtmt (ddklenkppd )
UEGW2016	Not Applicable	Hepatic Veno-Occlusive Disease	-	Beraprost sodium	(clxpkjumxl) = irynabguqh iefjcnmpze (deodywslij ) View more	-	01 Oct 2016
				Control (saline)	(clxpkjumxl) = kbznfkwmvt iefjcnmpze (deodywslij ) View more
BEAT study (ERS2015)	Phase 3	-	-	Beraprost-314d	aocaozkkly(rcseijdwev) = Beraprost-314d relaxed constricted PAs with a 4-fold greater potency than beraprost yxfmozehrv (lebenxclml ) View more	-	01 Sep 2015
				Beraprost
Kidney Week 2012 \| P-IIb/III study of BPS (ASN2013)	Phase 2/3	Kidney Failure, Chronic \| Glomerulonephritis	-	Beraprost Sodium (GN rats)	(cyprkyhkio) = egkhddnzmk gmlunjwprr (bvuctdlgov )	Positive	05 Nov 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis